Lytix Biopharma As
Records under this name other than the patents Lytix Biopharma As holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,598,114 | Antimicrobial compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,556,223 | Antimicrobial compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,085,608 | Treatment of biofilms Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,231,954 | Neurodegenerative Therapies Formerly held In force · High confidence | In force | High confidence | |
| US 8,283,315 | Inhibition of tumour growth Term ended Term ended Dec 18, 2020 · USPTO record | Term ended | Term ended Dec 18, 2020 | USPTO record |
| US 7,439,228 | Bioactive Peptides Held by another company Lapsed on the fee record Ended Oct 21, 2020 · High confidence | Lapsed on the fee record | Ended Oct 21, 2020 | High confidence |
| US 9,212,202 | Methods of peptide modification Lapsed on the fee record Ended Dec 15, 2019 · USPTO record | Lapsed on the fee record | Ended Dec 15, 2019 | USPTO record |
| US 8,048,852 | Antimicrobial compounds and formulations Lapsed on the fee record Ended Nov 1, 2019 · USPTO record | Lapsed on the fee record | Ended Nov 1, 2019 | USPTO record |
| US 8,143,211 | Bioactive Peptides No holder on record Term ended Ended no later than Aug 31, 2019 · Medium confidence | Term ended | Ended no later than Aug 31, 2019 | Medium confidence |
| US 9,115,169 | Method of treating tumors Lapsed on the fee record Ended Aug 25, 2019 · USPTO record | Lapsed on the fee record | Ended Aug 25, 2019 | USPTO record |